Detalles de la búsqueda
1.
Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men.
Diabetes Obes Metab
; 18(2): 178-85, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26636423
2.
Glucagon-like peptide-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in patients with type 2 diabetes: a randomized trial.
Diabetes Obes Metab
; 18(3): 281-8, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26640129
3.
Is insulin the most effective injectable antihyperglycaemic therapy?
Diabetes Obes Metab
; 17(2): 145-51, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25323312
4.
Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans.
Diabetes Obes Metab
; 17(9): 878-86, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26094857
5.
Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials.
Nutr Metab Cardiovasc Dis
; 25(10): 898-905, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26232910
6.
Diabetes-specific emotional distress in people with Type 2 diabetes: a comparison between primary and secondary care.
Diabet Med
; 31(10): 1252-9, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24766062
7.
Sex-specific effects of naturally occurring variants in the dopamine receptor D2 locus on insulin secretion and type 2 diabetes susceptibility.
Diabet Med
; 31(8): 1001-8, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24724616
8.
Postprandial microvascular function deteriorates in parallel with gradual worsening of insulin sensitivity and glucose tolerance in men with the metabolic syndrome or type 2 diabetes.
Diabetologia
; 56(3): 583-7, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23178932
9.
Effects of induced hyperinsulinaemia with and without hyperglycaemia on measures of cardiac vagal control.
Diabetologia
; 56(6): 1436-43, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23404443
10.
Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
Diabetes Obes Metab
; 15(7): 593-606, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23216746
11.
Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study.
Diabetologia
; 55(4): 915-25, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22237690
12.
Impaired insulin sensitivity is accompanied by disturbances in skeletal muscle fatty acid handling in subjects with impaired glucose metabolism.
Int J Obes (Lond)
; 36(5): 709-17, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-21712806
13.
Acute plasma amylase increase after glucagon-like peptide -1 receptor agonist exenatide administration in Type 2 diabetes.
Diabet Med
; 34(4): 591-592, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-27278095
14.
Glucocorticoid receptor gene polymorphisms are associated with reduced first-phase glucose-stimulated insulin secretion and disposition index in women, but not in men.
Diabet Med
; 29(8): e211-6, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22507373
15.
Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence.
Diabetes Obes Metab
; 14(2): 101-11, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21752172
16.
GLP-1 based therapies: differential effects on fasting and postprandial glucose.
Diabetes Obes Metab
; 14(8): 675-88, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22233527
17.
Does interference with the renin-angiotensin system protect against diabetes? Evidence and mechanisms.
Diabetes Obes Metab
; 14(7): 586-95, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22226145
18.
Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment.
Diabetes Obes Metab
; 14(6): 546-54, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22236356
19.
The longitudinal association between glycaemic control and health-related quality of life following insulin therapy optimisation in type 2 diabetes patients. A prospective observational study in secondary care.
Qual Life Res
; 21(8): 1359-65, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22065281
20.
Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial.
Diabetologia
; 54(8): 2103-12, 2011 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21562755